Johnson & Johnson (stock code: 00013) announced that the SAFFRON global phase III study of the combination therapy of Votrient and Tarceva for patients with specific lung cancer who have disease progression after Tarceva treatment and MET overexpression and/or amplification has completed patient enrollment.

Zhtng Cijng APP news, Hutchison MediPharma (00013) announced that the SAFFRON study has completed patient enrollment. SAFFRON is a global Phase III study designed to evaluate the combination therapy of Orpathys (savolitinib) and Tagrisso (osimertinib) in the treatment of locally advanced or metastatic non-small cell lung cancer patients with epidermal growth factor receptor ("EGFR") mutations, accompanied by MET overexpression and/or amplification, who have progressed after previous treatment with Tagrisso. The last patient in the study completed enrollment on October 31, 2025.